MUC-1 mucin expression in invasive areas of intraductal papillary mucinous tumors of the pancreas

Pathology International

Volumn 48, Issue 4, 1998, Pages 319-322

  Yonezawa, Suguru ^a   Taira, Michiko ^a   Osako, Masahiko ^b   Kubo, Masaaki ^a   Tanaka, Sadao ^b   Sakoda, Koro ^b   Takao, Sonshin ^a   Aiko, Takashi ^a   Yamamoto, Masaya ^c   Irimura, Tatsuro ^c   Kim, Young S ^d   Sato, Eiichi ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b Kagoshima City Hospital   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Intraductal papillary mucinous tumor; Invasion; MUC 1 mucin; Pancreas

Indexed keywords

MONOCLONAL ANTIBODY; MUC 1 MUCIN; MUCIN; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER INVASION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; MUCINOUS CARCINOMA; PANCREAS TUMOR; PRIORITY JOURNAL;

EID: 15144354735     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.1998.tb03913.x     Document Type: Letter

References (15)

1. Osako M, Yonezawa S, Siddiki B et al. Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors. Cancer 1993; 71: 2191-2199.
2. Yonezawa S. Application of immunohistochemistry for diagnosis of neoplasms: Mucin antigens expression and biological behavior. Acta Histochem. Cytochem. 1994; 27: 561-566.
3. Sessa F, Solcia E, Capella C et al. Intraductal papillary-mucinous tumours represent a distinct group of pancreatic neoplasms: An investigation of tumour cell differentiation and K-ras, p53 and c-erbB-2 abnormalities in 26 patients. Virchows Archiv. 1994; 425: 357-367.
4. Yamashita K, Yonezawa S, Tanaka S et al. Immunohistochemical study of mucin carbohydrates and core proteins in hepatolithiasis and cholangiocarcinoma. Int. J. Cancer 1993; 55: 82-91.
5. Tashiro Y, Yonezawa S, Kim YS, Sato E. Immunohistochemical study of mucin carbohydrates and core proteins in human ovarian tumors. Hum. Pathol. 1994; 25: 364-372.
6. Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984; 3: 223-232.
7. Siddiqui J, Abe M, Hayes D, Shani E, Yunis E, Kufe D. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc. Natl Acad. Sci. USA 1988; 85: 2320-2323.
8. Abe M, Kufe D. Characterization of cis-acting elements regulating transcription of the human DF3 breast carcinoma-associated antigen (MUC1) gene. Proc. Natl Acad. Sci. USA 1993; 90: 282-286.
9. Yamamoto M, Bhavanandan VP, Nakamori S, Irimura T. A novel monoclonal antibody specific for sialylated MUC1 mucin. Jpn. J. Cancer Res. 1996; 87: 488-496.
10. Gum JR, Byrd JC, Hicks JW, Toribara NW, Lamport DTA, Kim YS. Molecular cloning of human intestinal mucin cDNAs: Sequence analysis and evidence for genetic polymorphism. J. Biol. Chem. 1989; 264: 6480-6487.
11. Byrd JC, Ho JL, Lamport DTA et al. Relationship of pancreatic cancer apomucin to mammary and intestinal apomucins. Cancer Res. 1991; 51: 1026-1033.
12. Toribara NW, Gum JR, Culhane PJ et al. MUC-2 human small intestinal mucin gene structure: Repeated arrays and polymorphism. J. Clin. Invest. 1991; 88: 1005-1013.
13. Ligtenberg MJL, Buijs F, Vos HL, Hilkens J. Suppression of cellular aggregation by high level of episialin. Cancer Res. 1992; 52: 2318-2324.
14. van de Wiel-van Kemenade E, Ligtenberg MJL, de Boer AJ et al. Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J. Immunol. 1993; 151: 767-776.
15. Wesseling J, Van Der Valk SW, Vos HL, Sonnenberg A, Hilkens J. Episialin (MUC1) over-expression inhibits integrin-mediated cell adhesion to extracellular matrix components. J. Cell Biol. 1995; 129: 255-265.